Design Therapeutics, Inc.
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
Inclusion Criteria: * Participant is scheduled to undergo a keratoplasty for management of FECD independent of this study. * ≥30 years of age (inclusive). * Documented diagnosis of FECD in the study eligible eye. * Confirmation of positive TCF4 allele 18.1 CTG expansion in at least one allele. * Capable of giving signed informed consent. Exclusion Criteria: * Any ocular or medical condition in the study eligible eye which is clinically significant or would confound study results or data interpretation. * Any clinically significant medical, nonmedical, and psychiatric disorders that could pu…
Active
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.